These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17470825)

  • 1. Summaries for patients. Treatment of Crohn disease with anti-tumor necrosis factor agent.
    Ann Intern Med; 2007 Jun; 146(12):I20. PubMed ID: 17470825
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.
    Jordan N; Waghmare A; Abi-Ghanem AS; Moon A; Salvatore CM
    J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):294-6. PubMed ID: 21694635
    [No Abstract]   [Full Text] [Related]  

  • 3. GAIN for loss: adalimumab for infliximab-refractory Crohn disease.
    Mannon P
    Ann Intern Med; 2007 Jun; 146(12):888-90. PubMed ID: 17577009
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease].
    Michetti P
    Rev Med Suisse; 2008 Jan; 4(141):187-8. PubMed ID: 18335883
    [No Abstract]   [Full Text] [Related]  

  • 6. Methotrexate: the best choice for second-line maintenance treatment in active Crohn's disease?
    Grimaldi C
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):21-2. PubMed ID: 18977624
    [No Abstract]   [Full Text] [Related]  

  • 7. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis.
    Riolo G; Towheed TE
    J Rheumatol; 2012 Jan; 39(1):192-4. PubMed ID: 22210682
    [No Abstract]   [Full Text] [Related]  

  • 9. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD; Richards R
    Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
    Barthel HR; Gille T; Halbsguth A; Kramer M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
    Fanning SB; Chapman G; Yau Y; Leong RW
    J Gastroenterol Hepatol; 2010 Jan; 25(1):215. PubMed ID: 20136975
    [No Abstract]   [Full Text] [Related]  

  • 13. New onset of inflammatory polyarthritis in a patient taking adalimumab.
    Lee M; Petroniene R; Thorne C
    J Rheumatol; 2009 Mar; 36(3):660. PubMed ID: 19286867
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytokine-based therapies for Crohn's disease--new paradigms.
    Cominelli F
    N Engl J Med; 2004 Nov; 351(20):2045-8. PubMed ID: 15537904
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
    Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
    Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
    Sorrentino D; Terrosu G; Vadalà S; Avellini C
    Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
    [No Abstract]   [Full Text] [Related]  

  • 18. Basophil activation test in a case of systemic hypersensitivity reaction to infliximab with good tolerance to another anti-TNF-alpha agent (adalimumab).
    Manso L; Polo B; Fernández-Nieto M; Sastre LB; del Pozo V; Sastre J
    J Investig Allergol Clin Immunol; 2010; 20(6):537-8. PubMed ID: 21243942
    [No Abstract]   [Full Text] [Related]  

  • 19. Rheumatic fever in a patient receiving infliximab therapy for Crohn disease.
    Abu-El-Haija M; Stasheff S; Atkins DL; Bishop WP
    J Pediatr Gastroenterol Nutr; 2011 Mar; 52(3):360-1. PubMed ID: 21150656
    [No Abstract]   [Full Text] [Related]  

  • 20. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.